Skip to main content

Advertisement

Table 4 Response to treatment over 28-day follow-up among participants with enrollment parasitemia <200,000 parasites/μL in a therapeutic efficacy study in Machinga, Nkhotakota, and Karonga Districts in Malawi, 2014 (n = 426)

From: In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014

Estimate AL ASAQ
Total (n = 321) Site Total (n = 105)
Machinga (n = 112) Nkhotakota (n = 104) Karonga (n = 105)
Participants lost to follow-up, n (%) 33 (10.3) 14 (12.5) 14 (13.5) 5 (4.8) 15 (14.3)
Treatment failure, n (%)
 Early 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Late* 70 (24.3) 22 (22.5) 30 (33.3) 18 (18) 2 (2.2)
  Day of failure, median (range) 21 (14, 28) 24.5 (14, 28) 21 (14, 28) 21 (14, 28) 17.5 (14, 21)
  Reinfection* 68 (23.6) 22 (22.5) 30 (33.3) 16 (16) 1 (1.1)
  Recrudescence 2 (0.7) 0 (0) 0 (0) 2 (2) 1 (1.1)
 Day 3 clearance,  % (95 % CI)a 99.7 (97.5–100) 99.1 (94.5–100) 100 (96.5–100) 100 (96.6–100) 100 (96.6–100)
ACPR,  % (95 % CI)b
 Uncorrected 75.7 (70–80.5) 77.6 (68–83.4) 67.7 (56–76.3) 82 (73.1–89) 97.8 (92.2–99.7)
 PCR-corrected 99.3 (97.5–99.9) 100 (96.3–100) 100 (96–100) 98 (93–100) 99 (94–100)
Kaplan–Meier survival rate on day 28, % (95 % CI)c
 Uncorrected 76.3 (71.4–81.2) 78.2 (70.2–86.3) 67.4 (58–77.1) 82.2 (74.8–89.7) 97.9 (95–100)
 PCR-corrected 99.3 (98.3–100) 100d 100d 97.9 (94.9–100) 99.0 (96.9–100)
  1. * Significant difference between study sites (p < 0.05)
  2. aPercent day 3 clearance was estimated only among participants still enrolled in the study on day 3
  3. bAdequate clinical and parasitologic response (ACPR) was estimated only among participants who reached a valid study endpoint
  4. cThe Kaplan–Meier cumulative survival rate estimate included all study participants who contributed person-days during the 28-day follow-up
  5. dFor Kaplan–Meier cumulative survival rates of 100 %, confidence intervals were not estimated